Terms: = Pancreatic cancer AND Ki-67 AND Prognosis
259 results:
1. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract] [Full Text] [Related]
2. Usefulness of intratumoral perfusion analysis for assessing biological features of non-functional pancreatic neuroendocrine neoplasm.
Notake T; Shimizu A; Kubota K; Sugenoya S; Umemura K; Goto T; Yamada A; Fujinaga Y; Soejima Y
Langenbecks Arch Surg; 2024 Jan; 409(1):38. PubMed ID: 38221590
[TBL] [Abstract] [Full Text] [Related]
3. High-grade Solid Pseudopapillary Neoplasms of the Pancreas: Distinct Clinicopathological Malignant Features With Intriguing Gene Alterations through a Comparison With the Conventional Type.
Honda S; Yamaguchi H; Aimono E; Hara S; Minamiguchi S; Norose T; Ohike N; Yamochi T; Yasuda M; Moriya T; Shiko Y; Nishihara H; Nagao T
Am J Surg Pathol; 2024 Mar; 48(3):353-363. PubMed ID: 38189381
[TBL] [Abstract] [Full Text] [Related]
4. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract] [Full Text] [Related]
5. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.
Vesterinen T; Peltola E; Leijon H; Hannula P; Huhtala H; Mäkinen MJ; Nieminen L; Pirinen E; Rönty M; Söderström M; Jaatinen P; Arola J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894845
[TBL] [Abstract] [Full Text] [Related]
7. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
8. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
Koh Y; Kim H; Joo SY; Song S; Choi YH; Kim HR; Moon B; Byun J; Hong J; Shin DY; Park S; Lee KH; Lee KT; Lee JK; Park D; Lee SH; Jang JY; Lee H; Kim JA; Yoon SS; Park JK
J Transl Med; 2023 Oct; 21(1):730. PubMed ID: 37848935
[TBL] [Abstract] [Full Text] [Related]
9. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract] [Full Text] [Related]
10. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.
Gudmundsdottir H; Habermann EB; Vierkant RA; Starlinger P; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Halfdanarson TR; Nagorney DM; Cleary SP
Ann Surg Oncol; 2023 Aug; 30(8):4840-4851. PubMed ID: 37208566
[TBL] [Abstract] [Full Text] [Related]
11. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract] [Full Text] [Related]
12. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer.
Batbayar C; Ishii N; Harimoto N; Yokobori T; Saito H; Gantumur D; Gombodorj N; Erkhem-Ochir B; Muranushi R; Hoshino K; Yamanaka T; Hagiwara K; Tsukagoshi M; Watanabe A; Araki K; Hosouchi Y; Shirabe K
Int J Clin Oncol; 2023 Jul; 28(7):901-912. PubMed ID: 37119370
[TBL] [Abstract] [Full Text] [Related]
13. Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
[TBL] [Abstract] [Full Text] [Related]
14. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in pancreatic cancer.
Kano MT; Kokuryo T; Baba T; Yamazaki K; Yamaguchi J; Sunagawa M; Ogura A; Watanabe N; Onoe S; Miyata K; Mizuno T; Uehara K; Igami T; Yokoyama Y; Ebata T; Nagino M
Anticancer Res; 2023 Mar; 43(3):1009-1016. PubMed ID: 36854520
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Pan-cancer Analysis of KIF18A as a Marker for prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract] [Full Text] [Related]
16. Recurrence and outcomes of non-functional pancreatic neuroendocrine tumours post-resection: an Australian retrospective, multicentre cohort study.
Lim S; Chong L; Peeroo S; Onasanya O; He E; Banting S; Croagh D
ANZ J Surg; 2023 Jan; 93(1-2):160-165. PubMed ID: 36562118
[TBL] [Abstract] [Full Text] [Related]
17. SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate cancer Growth and Migration.
Eguchi T; Csizmadia E; Kawai H; Sheta M; Yoshida K; Prince TL; Wegiel B; Calderwood SK
Cells; 2022 Dec; 11(24):. PubMed ID: 36552758
[TBL] [Abstract] [Full Text] [Related]
18. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.
Loosen SH; Kostev K; Eschrich J; Krieg S; Krieg A; Luedde T; Jann H; Roderburg C
Medicine (Baltimore); 2022 Dec; 101(50):e32044. PubMed ID: 36550801
[TBL] [Abstract] [Full Text] [Related]
19. Calcifications and Cystic Morphology on Preoperative Imaging Predict Survival After Resection of pancreatic Neuroendocrine Tumors.
Makris EA; Cannon JGD; Norton JA; Lopez-Aguiar AG; Dillhoff M; Beal E; Idrees K; Smith PM; Rocha FG; Kanji Z; Cho C; Beems M; Weber S; Fisher A; Krasnick BA; Fields RC; Maithel SK; Poultsides GA
Ann Surg Oncol; 2023 Apr; 30(4):2424-2430. PubMed ID: 36434481
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract] [Full Text] [Related]
[Next]
